Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancerMehmet Altan, David L. Rimm|npj Breast Cancer|2018Cited by 59
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance statusJoao V. Alessi, Mark M. Awad, E. Jimenez-Aguilar et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 58
High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLCMehmet Altan, Jianjun Zhang|Journal for ImmunoTherapy of Cancer|2024Cited by 13